Losartan formulations comparison
Pro Research Analysisby 
Searched over 200M research papers
Bioequivalence of Losartan Tablet Formulations
Multiple studies have compared different brands and formulations of losartan tablets to determine if they are bioequivalent, meaning they provide similar levels of the drug in the body. Research comparing 50 mg and 100 mg losartan tablets from various manufacturers found that the test and reference products had similar pharmacokinetic profiles, with key parameters like Cmax (maximum concentration), AUC0-t (area under the curve), and AUC0-∞ all falling within the accepted bioequivalence range of 80–125%12. This means generic versions, such as those from Julphar and Caplin Point Laboratories, are considered interchangeable with the original Cozaar® brand for clinical use12.
Losartan Combination Formulations: Fixed-Dose and Bilayer Tablets
Studies have also evaluated fixed-dose combinations (FDCs) of losartan with other drugs, such as hydrochlorothiazide and amlodipine. Research on losartan/hydrochlorothiazide tablets showed that generic and reference products were bioequivalent in both Asian Indian and Japanese volunteers, with no significant differences in drug absorption or safety between ethnic groups. Similarly, a triple FDC tablet containing amlodipine, losartan, and rosuvastatin was found to have pharmacokinetic equivalence to the separate administration of these drugs, supporting its use for improved patient compliance.
Bilayer tablets combining losartan with hydrochlorothiazide have been developed using direct compression methods. These formulations were optimized for mechanical properties and drug release, and animal studies showed no significant differences in bioavailability compared to the marketed Hyzaar® tablet. Additionally, gastro-retentive floating bilayer tablets have been designed to provide both immediate and sustained release of losartan and hydrochlorothiazide, achieving over 95% drug release in 12 hours and maintaining stability under accelerated conditions.
Novel Losartan Formulations: Sustained Release, Fast Dissolving, and SEDDS
To address losartan’s short half-life and variable bioavailability, researchers have developed sustained-release matrix tablets using various polymers. These formulations can maintain drug release for up to 24 hours, potentially improving blood pressure control and patient adherence. Multiparticulate pellet systems using Eudragit polymers have also been shown to provide controlled, prolonged drug release, with optimized batches demonstrating favorable flow properties and sustained release profiles.
Fast-dissolving losartan tablets have been formulated using novel co-processed superdisintegrants, resulting in rapid drug release and improved onset of action. The combination and concentration of superdisintegrants significantly influenced the dissolution rate, with co-processed mixtures providing the fastest disintegration and drug release.
Self-emulsifying drug delivery systems (SEDDS) for losartan potassium have been developed to bypass first-pass metabolism and enhance bioavailability. The optimized SEDDS formulation showed similar dissolution and therapeutic efficacy to marketed tablets, but at half the dose, indicating improved efficiency.
Conclusion
Research consistently shows that generic losartan tablet formulations are bioequivalent to branded products, ensuring similar efficacy and safety. Advances in formulation technology, including sustained-release, fast-dissolving, multiparticulate, and self-emulsifying systems, offer improved drug release profiles, better patient compliance, and potentially enhanced therapeutic outcomes. Combination and bilayer tablets further simplify treatment regimens for hypertension and related conditions, supporting their use as effective alternatives to standard formulations1234+6 MORE.
Sources and full results
Most relevant research papers on this topic